- Prime Medicine Press Release (NASDAQ:PRME): Q3 GAAP EPS of -$0.44 fails by $0.01.
- Revenue of $0.21 million fails for $5.7 million.
- As of September 30, 2024, pro forma cash, cash equivalents, investments and restricted cash amounted to $244.6 million. Cash, cash equivalents, investments and restricted cash were $189.6 million, compared to $135.2 million as of